Rheumatoid Arthritis
Conditions
Interventions
None listed
Sponsors
AbbVie GK
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Male or female. Adult (18 years old or older). 2.Has rheumatoid arthritis, diagnosed either by the 1987revised ACR classification criteria or by the 2010 ACR,EULAR classification criteria for RA. 3.Currently treated with any kind of approved csDMARDs, tsDMARDs or bDMARDs. 4.Has been exposed to no more than 2 bDMARDs at the time of the enrollment. 5.His,her RA is sub optimally controlled, despite full tolerable dose of current DMARD therapy administered for more than 3months Definition of suboptimal disease control,having high or moderate disease activity for at least 1 month but not more than for 4months prior to the enrollment. 6.Understands the language and willing,able to complete the patient reported outcome questionnaires. 7.Does not participate in any kind of clinical study for RA. 8.Has provided written authorization to the investigator to use and,or disclose personal and,or health data, or informed consent if requested by the local regulations.
Exclusion criteria
Exclusion criteria: -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess treatment satisfaction of patients with sub optimally controlled RA treated with conventional/targeted synthetic or biological DMARDs. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To assess the sociodemographic, clinical, functional, adherence and quality of life characteristics of sub optimally controlled RA patients treated with conventional/targeted synthetic or biological DMARDs. 2.To assess healthcare resource utilization (HRU) during 12 months prior to enrollment to the study in sub optimally controlled RA patients treated with conventional/targeted synthetic or biological DMARDs. 3.To assess electronic health literacy of sub optimally controlled RA patients treated with conventional/targeted synthetic or biological DMARDs. 4.To assess expectations towards RA therapy, medication preferences and needs for patient support of sub optimally controlled RA patients treated with conventional/targeted synthetic or biological DMARDs 5.To determine relationship between treatment satisfaction, its subdomains and patient characteristics. 6.To determine relationship between adherence and patient characteristics. 7.To determine relationship between medication preferences and patient characteristics. 8.To determine relationship between treatment expectations and patient characteristics. 9.To determine relationship between specific PSP-related needs and patient characteristics. | — |
Countries
Japan,Asia(except Japan),South America,Europe,Africa
Contacts
Public ContactTsuyoshi Harada
AbbVie GK Medical
Outcome results
None listed